CMS Open Payments · Program Year 2024
Kyowa Kirin, Inc.
Kyowa Kirin, Inc. reported $11,667,091.66 across General Payments, Research, and Ownership to 16,689 physicians and teaching hospitals across 17,707 transactions.
- $11.7M
- All-tracks total
- 17,707
- Transactions
- 16,689
- Recipients
- +$24.7K
- General Payments vs PY2023
Kyowa Kirin, Inc. reported $11,667,091.66 across all CMS Open Payments tracks (General + Research + Ownership) to 16,689 physicians and teaching hospitals in Program Year 2024 - ranking #148 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $2,523,749.59, averaging $699.09 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer kyowa-kirin-inc Kyowa Kirin, Inc.
$11.7M · #148/1,925 · 0.1% industry · PY2024
- TOT $11.7M
- RANK #148
- SHARE 0.1%
- TXN 17,707
- RCP 16,689
- CAT 6
- GEN $2.5M
- ΔGEN +$24.7K
- TOP1 4.9%
- PY 2024
Volume peers
Nearest volume peer: Genmab A/S ($11.6M)
Kyowa Kirin, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Kyowa Kirin, Inc.'s CMS-reported General Payments increased by $24.7K (+1.0%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: KYOWA KIRIN, INC.PY2023: KYOWA KIRIN, INC.PY2024: Kyowa Kirin, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $2,499,099.57
- PY2024
- $2,523,749.59
What the Data Shows for Kyowa Kirin, Inc.
$11,667,091.66: that is what Kyowa Kirin, Inc. reported in payments to 16,689 physicians and teaching hospitals during Program Year 2024, spread across 17,707 transactions ($658.90 per transaction, $699.09 per recipient). The company sits at rank #148 of 1,925, a comparatively small 0.1% slice of all industry payments reported nationwide for the year.
The 6-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Compensation for Services Other Than Consulting" at $1.2M, accounting for 46.4% of this company's General Payments and 344 transactions.
General Payment Breakdown by Type
Across 6 types of general payments, Kyowa Kirin, Inc.'s largest category was "Compensation for Services Other Than Consulting" at $1.2M - 46.4% of General Payments.
Kyowa Kirin, Inc. reports 6 general-payment categories - the top three are Compensation for Services Other Than Consulting (46.4%), Food and Beverage (17.5%), and Space Rental or Facility Fees (13.9%). The remaining 3 categories make up 22.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Kyowa Kirin, Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $1.2M | 344 | 46.4% |
| Food and Beverage | $441.9K | 14,918 | 17.5% |
| Space Rental or Facility Fees | $351.3K | 89 | 13.9% |
| Consulting Fee | $330.1K | 113 | 13.1% |
| Travel and Lodging | $225.8K | 1,098 | 8.9% |
| Education | $3.0K | 127 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $395,553.94 (15.7%) of $2,523,749.59 in this company's General Payments records across 9,015 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Kyowa Kirin, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
City Of Hope National Medical Ctr
$124,296.00 across 14 reported transactions
- 2
Jill Giordano Farmer
$74,984.63 across 85 reported transactions
- 3
Oleg Akilov
$71,231.84 across 97 reported transactions
- 4
Eric Rush
$66,624.92 across 75 reported transactions
- 5
Joshua Yang
$58,416.55 across 105 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Kyowa Kirin, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Kyowa Kirin, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Kyowa Kirin, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Orthofix Medical, Inc.
Inari Medical, Inc.
Phathom Pharmaceuticals, Inc.
Catalyst OrthoScience
Iovance Biotherapeutics, Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.